It is noteworthy that the first cancer immunotherapy approved by the Food and Drug Administration (FDA) was recombinant IFNα therapy; however, the development of severe systemic autoimmune reactions was observed in certain individuals as a side effect [217]. The gene discussed is IFNA2; the disease is cancer.